Ulcerative Colitis (UC) Drug Market: Size, Share, Growth, Trends, Company Profiles, and Forecast 2030
Ulcerative colitis (UC) is a chronic inflammatory bowel disease that affects the colon and rectum. The disease is characterized by ulcerations, inflammation, and bleeding in the colonic mucosa, which leads to diarrhea and abdominal pain. The market for UC drugs has been growing in recent years due to the increasing prevalence of UC, as well as advancements in drug development and treatment options.
The global Ulcerative Colitis (UC) Drug Market was valued at USD 7.80 billion in 2021 and is expected to grow at a CAGR of 5.1% during the forecast period (2023-2030). The increasing demand for effective and innovative treatments, coupled with the growing awareness about UC, is expected to drive the market growth.
Get a sample of the report @ https://www.reportsanddata.com/download-free-sample/2379
These key highlights from the ulcerative colitis drug market report provide a valuable insight into the market trends and drivers. The biologics segment is expected to dominate the market due to its ability to selectively target the affected area, resulting in fewer side effects and increased preference among healthcare providers and patients. The immunomodulators segment is predicted to have the highest revenue growth rate, as they are used when other treatments have failed.
North America is expected to hold the largest market share due to the sophisticated healthcare system and high awareness of UC. The high prevalence of UC and Crohn’s disease, as well as the presence of established healthcare systems and high risk of lifestyle-related factors, are driving the growth of the market in this region. The market is further driven by the strong product pipelines of major players and increased research activities.
The recent approval of SKYRIZI by the FDA as the first and only specific Interleukin-23 (IL-23) treatment for moderate to highly active Crohn’s disease in adults is a significant development in the market. This highlights the growing focus on the development of innovative and effective treatments for UC.
The report also sheds light on leading players in the market with details about their global position, revenue contribution, financial standing, product portfolio and license agreement. The global Ulcerative Colitis (UC) Drug market is extremely competitive and comprise global and regional market players. These players are focused on adopting various strategies such as mergers and acquisitions, collaborations, and government partnerships, research and development activities and introducing novel products to strengthen their market position. Some of the key players operating in the global market are Johnson & Johnson Services, Inc., AbbVie Inc., Takeda Pharmaceutical Company Limited, Pfizer Inc., Bristol-Myers Squibb Company, EA Pharma Co., Ltd., Elli Lilly and Company, Novartis AG, Merck & Co., Inc., Reistone Biophrma, and Bausch Health Companies Inc.
Ulcerative Colitis (UC) Drug Market Segmentation:
Segmentation by Product Type The global UC drug market can be segmented into biologic drugs and small molecule drugs. Biologic drugs, such as anti-TNF agents, are expected to hold a significant share of the market due to their high efficacy and growing demand. Small molecule drugs, such as 5-aminosalicylic acid (5-ASA) drugs, are also widely used for the treatment of UC.
Segmentation by Devices Categories The global UC drug market can also be segmented into oral and topical devices. Oral devices, such as tablets and capsules, are widely used for the treatment of UC due to their ease of administration. Topical devices, such as enemas and foams, are also commonly used for the treatment of UC, particularly for patients with more severe symptoms.
End-User Outlook The global UC drug market caters to patients with UC, as well as healthcare providers, such as hospitals, clinics, and specialty care centers. The increasing prevalence of UC and the growing demand for effective treatments are expected to drive the market growth among end-users.
Further the research report offers details about 5 major regions covered in the global Ulcerative Colitis (UC) Drug market.
Regional analysis covers:
- North America
- Asia Pacific
- Latin America
- Middle East & Africa
Request a customization of the report @ https://www.reportsanddata.com/request-customization-form/2379
Thank you for reading the report. Also note that we offer report customization as per client requirement. Kindly connect with us to know more about the customization feature and our team will provide a well-suited report as per your requirement.
Get Explore Latest Research Report by Reports and Data:
Clinical Microbiology Market @ https://www.biospace.com/article/clinical-microbiology-market-size-2022-2028-technological-advances-in-clinical-microbiology-are-predicted-to-spur-market-growth/
Erythrocyte Sedimentation Rate (ESR) Analyzers Market @ https://www.biospace.com/article/erythrocyte-sedimentation-rate-esr-analyzers-market-size-developments-status-trends-and-key-players-analysis-forecast-2027/
About Reports and Data
Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, TouchPoints, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provide our clients with the ability to secure an edge over their respective competitors.
Head of Business Development
Reports and Data | Web: www.reportsanddata.com
Direct Line: +1-212-710-1370
E-mail: [email protected]